ArticleJournal of personalized medicine2021
Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.
Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Serum neurofilament light chain and glial fibrillary acidic protein for predicting response to apheresis in steroid-refractory multiple sclerosis relapses.European journal of neurology · 2024Trial
- Neural Stem Cells in Multiple Sclerosis: A Comprehensive Review of Preclinical and Clinical Evidence for CNS Repair and Translational Hurdles.Applied biochemistry and biotechnology · 2026Review
- Article
- Viral associations in multiple sclerosis: pathogenetic mechanisms and therapeutic implications.Virology journal · 2026Review
- Bodily experiences in multiple sclerosis: functional neurological symptoms, body image dissatisfaction, and disordered eating behaviors. A narrative review.Frontiers in psychology · 2026Review
- Characteristics of Disease Relapses and Their Relationships with Weather Conditions in Patients with Multiple Sclerosis.Journal of clinical medicine · 2025Article
- Neurofilament Biomarkers in Neurology: From Neuroinflammation to Neurodegeneration, Bridging Established and Novel Analytical Advances with Clinical Practice.International journal of molecular sciences · 2025Review
- Multiple sclerosis: molecular pathogenesis and therapeutic intervention.Signal transduction and targeted therapy · 2025Review
- Infection, Relapses, and Pseudo-Relapses in Individuals With Multiple Sclerosis.Neurology. Clinical practice · 2025Article
- Exploring the Clinical Utility of Neurofilament Light Chain Assays in Multiple Sclerosis Management.Neurology(R) neuroimmunology & neuroinflammation · 2025Review
- Advancements in multiple sclerosis.Internal medicine journal · 2025Review
- Liver Injury Following Intravenous Methylprednisolone Pulse Therapy in Multiple Sclerosis: The Experience from a Single Academic Liver Center.Biomolecules · 2025Article
- Review
- New diagnosis of multiple sclerosis in the setting of recent Sinopharm COVID-19 vaccine (BBIBP-CorV) exposure: A series of clinical cases and updated review of the literature.Current journal of neurology · 2024Article
- Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosis.Frontiers in immunology · 2024Article
- Genetic susceptibility and causal pathway analysis of eye disorders coexisting in multiple sclerosis.Frontiers in immunology · 2024Article
- Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses.Journal of neuroinflammation · 2022Observational
- Personalized Diagnosis and Therapy for Multiple Sclerosis.Journal of personalized medicine · 2022Article
- Estrogen, the Peripheral Immune System and Major Depression - A Reproductive Lifespan Perspective.Frontiers in behavioral neuroscience · 2022Review
- Plasma Exchange vs. Immunoadsorption: Effects on Immunological Markers and Predictive Value in Steroid-Refractory MS Attacks.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Minimizing the risk of relapse is essential in multiple sclerosis (MS). As none of the treatments currently available are capable of completely preventing relapses, treatment of these episodes remains a cornerstone of MS care. The objective of this manuscript is to reduce uncertainty and improve quality of care of this neurological process. This article addresses definitions of key concepts, recommendations for clinical examination, classification criteria, magnetic resonance imaging, biomarkers, and specific therapeutic counsels including special populations such as pregnant and breastfeeding women, and children. An algorithm for treating MS relapses is also provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.